Ocular hypertension means the pressure in your eyes — your intraocular pressure (IOP) — is higher than normal. Left untreated, high eye pressure can cause glaucoma and permanent vision loss in some individuals. Betaxolol is a beta-adrenergic blocking agent that is used for the treatment of glaucoma. When taken by mouth, betaxolol and other beta-adrenergic blocking agents act mainly by blocking the action of the sympathetic (adrenergic) nervous system, for example, on the heart. In addition to its effect on the heart, betaxolol reduces the pressure within the eye (intraocular pressure). This effect is thought to be caused by reducing the production of the liquid (called the aqueous humor) within the anterior chamber of the eye although the precise mechanism of its effect is not known. 
The release of the Ocular Hypertension Pipeline ReviewH2 2014 was encouraging for ophthalmologic research and development teams regarding the use of Betaxolol to treat ocular hypertension. The review, published in early 2015, focused on the positive aspects of various therapies for treating ocular hypertension, with Betaxolol receiving positive feedback. The global therapeutic landscape for both preventing and treating ocular hypertension has experienced an overwhelming need for attention, particularly with the aging population worldwide. Betaxolol has been proven to be an efficacious product in various studies over the past decade, and the safety record of this targeted therapy is sound.
Defined as an increase in the pressure of the eye/eyes, ocular hypertension is not an interchangeable diagnosis with glaucoma. Ocular hypertension typically shows no damage to the structure of the eyes, or detectable vision changes in patients, which is opposite of what patients with glaucoma experience. While glaucoma often leads to optic nerve damage and progressive vision loss, ocular hypertension usually has no signs or symptoms. Statistically people who are African American and over the age of forty are diagnosed with ocular hypertension. Other known risk factors for this condition include a family history of ocular hypertension or glaucoma, diabetes and extreme nearsightedness. An increased risk of glaucoma is present for those patients diagnosed with ocular hypertension, so annual eye exams are prudent for this patient population.
See more at: http://www.lgmpharma.com/blog/betaxolol-remains-a-standard-treatment-for-ocular-hypertension/#sthash.8AwM5owC.dpuf
 
Source: LGM Pharma

On